PMID- 23406805
OWN - NLM
STAT- MEDLINE
DCOM- 20131205
LR  - 20211203
IS  - 1576-8260 (Electronic)
IS  - 0004-0614 (Linking)
VI  - 66
IP  - 1
DP  - 2013 Jan-Feb
TI  - Molecular markers for ischemia, do we have something better then creatinine and 
      glomerular filtration rate?
PG  - 99-114
AB  - Acute kidney injury (AKI) can occur spontaneously or iatrogenically, and rates of 
      AKI continue to rise over the last two decades despite improvements in clinical 
      care and development of preventive strategies. Serum creatinine (sCr) is the 
      current gold standard for measuring changes in kidney function and identifying 
      AKI. Detection of AKI by sCr, however, is delayed and small rises connote 
      significantly increased morbidity and mortality. Diagnosis of AKI by sCr is 
      therefore likely too late to prevent some of the early structural changes that 
      characterize renal injury. Several urinary biomarkers including neutrophil 
      gelatinase-associated lipocalin (NGAL), N-acetyl-beta-D-glucosaminidase (NAG), 
      Interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1), liver 
      fatty-acid-binding protein (L-FABP), and cystatin-C, have shown an ability to 
      predict AKI days before an elevation in sCr, and a few even seem to predict 
      AKI-related morbidity and mortality better than sCr alone. A review of the 
      current literature regarding these biomarkers reveals that they individually have 
      unique strengths and weaknesses that can provide different types of information 
      about patients. Currently, NGAL is the urine biomarker with the most promise as 
      an individual marker. However, combining multiple markers to form a 'biomarker 
      panel' along with sCr is an improvement over current clinical risk prediction 
      models alone, and may be able to provide more individualized detail about the 
      type and location of renal injury.
FAU - Sprenkle, Preston
AU  - Sprenkle P
AD  - Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 
      New York, New York, USA.
FAU - Russo, Paul
AU  - Russo P
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - Spain
TA  - Arch Esp Urol
JT  - Archivos espanoles de urologia
JID - 0064757
RN  - 0 (Biomarkers)
RN  - 0 (Cystatin C)
RN  - 0 (Fatty Acid-Binding Proteins)
RN  - 0 (HAVCR1 protein, human)
RN  - 0 (HSP72 Heat-Shock Proteins)
RN  - 0 (Hepatitis A Virus Cellular Receptor 1)
RN  - 0 (Lipocalins)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Receptors, Virus)
RN  - AYI8EX34EU (Creatinine)
RN  - EC 3.2.1.31 (Glucuronidase)
RN  - EC 3.2.1.31 (Klotho Proteins)
RN  - EC 3.2.1.52 (Acetylglucosaminidase)
RN  - EC 3.4.21.37 (Leukocyte Elastase)
SB  - IM
MH  - Acetylglucosaminidase/blood
MH  - Acute Kidney Injury/blood/*diagnosis
MH  - Biomarkers/*analysis
MH  - Creatinine/*blood
MH  - Cystatin C/blood
MH  - Fatty Acid-Binding Proteins/analysis/metabolism
MH  - Glomerular Filtration Rate/*physiology
MH  - Glucuronidase/blood
MH  - HSP72 Heat-Shock Proteins/blood
MH  - Hepatitis A Virus Cellular Receptor 1
MH  - Humans
MH  - Kidney Function Tests/*standards
MH  - Klotho Proteins
MH  - Leukocyte Elastase/blood
MH  - Lipocalins/blood
MH  - Liver/metabolism
MH  - Membrane Glycoproteins/metabolism
MH  - Receptors, Virus/metabolism
EDAT- 2013/02/15 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/02/15 06:00
PHST- 2013/02/15 06:00 [entrez]
PHST- 2013/02/15 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
PST - ppublish
SO  - Arch Esp Urol. 2013 Jan-Feb;66(1):99-114.